Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Glaucoma: Overview01:25

Glaucoma: Overview

Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Inherited retinal disease genes with dual inheritance patterns: insights from the IRD-PT registry.

Journal of medical genetics·2026
Same author

Development of a predictive matrix for pre-test genetic counselling in inherited retinal diseases based on data from 1001 patients enrolled in the IRD-PT registry.

European journal of medical genetics·2026
Same author

Comparison of Intravitreal Antivascular Endothelial Growth Factor Therapy in Treatment-Naïve vs Panretinal Photocoagulation-Treated Eyes With Proliferative Diabetic Retinopathy.

Journal of vitreoretinal diseases·2026
Same author

Association of age-related macular degeneration with exposome related metabolomics.

Metabolomics : Official journal of the Metabolomic Society·2026
Same author

Visual stimulation therapy in spinocerebellar ataxia type 29: Case report.

European journal of ophthalmology·2026
Same author

[Value-Based Healthcare in the Treatment of Age-Related Macular Degeneration: Clinical and Patient-Reported Outcomes from a Portuguese Multicenter Study].

Acta medica portuguesa·2026
Same journal

The risk of retinal vascular events in patients using semaglutide: a scoping review.

Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde·2026
Same journal

Interpreting relative afferent pupillary defect in Leber hereditary optic neuropathy using interocular visual acuity difference.

Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde·2026
Same journal

1 MONTH VS. 3 MONTHS HEAVY SILICONE OIL TAMPONADE IN COMPLEX RHEGMATOGENOUS RETINAL REDETACHMENT.

Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde·2026
Same journal

Visual loss after silicone oil removal - Analysis of a German cohort.

Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde·2026
Same journal

Weekend effect on vitrectomy: Insights from a Nationwide Population-Based Study in Korea.

Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde·2026
Same journal

The Royal College of Ophthalmologists National Ophthalmology Database Age-Related Macular Degeneration Audit, Report 2: Baseline Characteristics, the Care Pathway and 12-Month Visual Acuity and Safety Outcomes for 54,882 Eyes Starting Treatment for Neovascular Age-Related Macular Degeneration.

Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde·2026
See all related articles

Related Experiment Video

Updated: May 20, 2026

A Gaze-Contingent Display Framework for Perceptual Learning Research with Simulated Central Vision Loss
07:12

A Gaze-Contingent Display Framework for Perceptual Learning Research with Simulated Central Vision Loss

Published on: April 11, 2025

Myopic maculopathy: a review.

Rufino Silva1

  • 1Faculty of Medicine, University of Coimbra, Department of Ophthalmology, Coimbra University Hospital, AIBILI: Association for Innovation and Biomedical Research on Light and Image, Coimbra, Portugal. rufino.silva@oftalmologia.co.pt

Ophthalmologica. Journal International D'Ophtalmologie. International Journal of Ophthalmology. Zeitschrift Fur Augenheilkunde
|August 1, 2012
PubMed
Summary
This summary is machine-generated.

Pathological myopia causes irreversible vision loss and blindness. This review covers high myopia, its associated choroidal neovascularization (CNV), and current controversial treatments.

More Related Videos

Scleral Cross-linking Using Riboflavin and Ultraviolet-A Radiation for Prevention of Axial Myopia in a Rabbit Model
05:56

Scleral Cross-linking Using Riboflavin and Ultraviolet-A Radiation for Prevention of Axial Myopia in a Rabbit Model

Published on: April 3, 2016

Ex Vivo OCT-Based Multimodal Imaging of Human Donor Eyes for Research into Age-Related Macular Degeneration
10:14

Ex Vivo OCT-Based Multimodal Imaging of Human Donor Eyes for Research into Age-Related Macular Degeneration

Published on: May 26, 2023

Related Experiment Videos

Last Updated: May 20, 2026

A Gaze-Contingent Display Framework for Perceptual Learning Research with Simulated Central Vision Loss
07:12

A Gaze-Contingent Display Framework for Perceptual Learning Research with Simulated Central Vision Loss

Published on: April 11, 2025

Scleral Cross-linking Using Riboflavin and Ultraviolet-A Radiation for Prevention of Axial Myopia in a Rabbit Model
05:56

Scleral Cross-linking Using Riboflavin and Ultraviolet-A Radiation for Prevention of Axial Myopia in a Rabbit Model

Published on: April 3, 2016

Ex Vivo OCT-Based Multimodal Imaging of Human Donor Eyes for Research into Age-Related Macular Degeneration
10:14

Ex Vivo OCT-Based Multimodal Imaging of Human Donor Eyes for Research into Age-Related Macular Degeneration

Published on: May 26, 2023

Area of Science:

  • Ophthalmology
  • Genetics
  • Epidemiology

Background:

  • Pathological myopia is a leading cause of irreversible vision loss globally.
  • Choroidal neovascularization (CNV) in pathological myopia significantly impairs vision, especially in younger individuals.
  • Recent advancements have improved understanding of high myopia and associated CNV.

Purpose of the Study:

  • To provide an updated review of pathological myopia, including its definition, progression, epidemiology, and genetics.
  • To review myopic choroidal neovascularization (CNV), covering its natural history, epidemiology, risk factors, and pathogenic mechanisms.
  • To discuss current treatment strategies for myopic CNV, acknowledging controversial outcomes.

Main Methods:

  • Literature review of recent scientific contributions.
  • Synthesis of data on pathological myopia and myopic CNV.
  • Analysis of epidemiological and genetic factors.

Main Results:

  • Pathological myopia is a significant global health concern.
  • Myopic CNV is a primary cause of vision impairment in young adults.
  • Treatment outcomes for myopic CNV remain under investigation and subject to debate.

Conclusions:

  • A comprehensive understanding of pathological myopia and CNV is crucial for effective management.
  • Further research is needed to clarify the efficacy and long-term effects of emerging treatments.
  • Continued investigation into risk factors and pathogenic mechanisms will guide future therapeutic development.